Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.
Authors
John W Myers
San Antonio Military Medical Center, San Antonio, TX
John W Myers, Garth S Herbert, Guy T Clifton, Timothy J Vreeland, Tommy A Brown, Kaitlin M. Peace, Julia M Greene, Doreen O Jackson, Diane F Hale, John S Berry, Mark B. Faries, George Earl Peoples
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses
Sub Track
Cell Therapies
Clinical Trial Registration Number
NCT02301611
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr TPS201)
DOI
10.1200/JCO.2018.36.5_suppl.TPS201
Abstract #
TPS201
Poster Bd #
N5
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The influence of harvest method on dendritic cell function and clinical outcomes in a randomized trial of a dendritic cell vaccine to prevent recurrences in high-risk melanoma.
First Author: Alexandra Adams
Poster
2019 ASCO Annual Meeting
Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.
First Author: Jessica Campf
Poster
2015 ASCO Annual Meeting
Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.
First Author: Julia M. Greene
Poster
2012 ASCO Annual Meeting
Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients.
First Author: Natalia N. Petenko